Table 2.
Univariate and multivariate analysis of the progression-free survival of patients treated with palbociclib and fulvestrant. ECOG PS, Eastern Cooperative Oncology Group Performance Status. LMR, lymphocyte-to-monocyte ratio. HR, hazard ratio. CI, confidence interval.
| Parameter | Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | p Value | Hazard Ratio | 95% CI | p Value | ||
| All Breast Cancers (n = 106) | |||||||
| Age | >65 years | 0.566 | 0.323–0.989 | 0.046 | 1.267 | 0.684–2.347 | 0.451 |
| ECOG PS | ≥1 | 0.429 | 0.195–0.942 | 0.035 | |||
| Histology | Lobular | 0.163 | 0.040–0.669 | 0.012 | |||
| KRAS | Positive | 20.746 | 9.576–44.946 | <0.001 | 3.053 | 1.112–8.383 | 0.030 |
| Copies/ml | 1.016 | 1.012–1.020 | <0.001 | ||||
| Metastases | >1 | 16.541 | 7.321–37.372 | <0.001 | |||
| Bone | 1.120 | 0.351–3.572 | 0.848 | ||||
| Lymph Nodes | 4.334 | 2.580–7.280 | <0.001 | ||||
| Liver | 2.987 | 1.792–4.980 | <0.001 | ||||
| Neutropenia | G3 | 0.803 | 0.484–1.330 | 0.393 | |||
| G4 | 0.399 | 0.212–0.751 | 0.004 | ||||
| Febrile | 0.345 | 0.125–0.953 | 0.040 | ||||